News
Sports
Life
Opinion
Business
Advertise
Obituaries
eNewspaper
Legals
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
NewsOK Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eagle Pharmaceuticals
(NQ:
EGRX
)
4.530
+0.550 (+13.82%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eagle Pharmaceuticals
< Previous
1
2
3
4
5
6
Next >
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
October 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (...
Via
Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
August 08, 2021
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
October 01, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...
Via
Benzinga
Exposures
Product Safety
Reminder: Eagle Pharmaceuticals to Host CAL02 Investor Event on September 9, 2021
September 07, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
September 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
September 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (...
Via
Benzinga
Eagle Pharmaceuticals to Present at September Healthcare Conferences
September 01, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
September 01, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) AC Immune SA (NASDAQ: ACIU...
Via
Benzinga
33 Stocks Moving In Tuesday's Mid-Day Session
August 31, 2021
Gainers AC Immune SA (NASDAQ: ACIU) shares jumped 68.4% to $11.77. AC Immune and its collaborating partner Genentech, part of Roche Holdings, announced topline data from Phase 2...
Via
Benzinga
55 Biggest Movers From Yesterday
September 01, 2021
Gainers Unico American Corporation (NASDAQ: UNAM) shares gained 59% to close at $4.15 on Tuesday. Elys Game Technology, Corp. (NASDAQ: ELYS) rose 43% to close at $6.62 after it...
Via
Benzinga
Eagle Pharmaceuticals Wins Vasopressin Patent Trial
August 31, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals Granted Additional Patent for Bendamustine Franchise
August 31, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
August 25, 2021
ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Agenus Inc. (NASDAQ: AGEN)...
Via
Benzinga
Exposures
COVID-19
Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe Pneumonia
August 25, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals, inc (EGRX) Q2 2021 Earnings Call Transcript
August 09, 2021
EGRX earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Eagle Pharmaceuticals In-Licenses US Rights For Emergency Hospital Product, Q2 Earnings Beat Consensus
August 09, 2021
Eagle Pharmaceuticals Inc (NASDAQ: EGRX) has entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH for the commercial rights to its product,...
Via
Benzinga
Topics
Earnings
Exposures
Financial
Recap: Eagle Pharmaceuticals Q2 Earnings
August 09, 2021
Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were up 63.16% year over year to $0...
Via
Benzinga
Eagle Pharmaceuticals Reports Second Quarter 2021 Results
August 09, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals Announces Licensing Agreement with AOP Orphan for U.S. Commercial Rights to Landiolol, a Beta-1 Adrenergic Blocker
August 09, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals to Host Second Quarter 2021 Financial Results on August 9, 2021
July 28, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals Announces FDA Maintains Prioritization of ANDA for Vasopressin
June 24, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals: Return On Capital Employed Insights
June 22, 2021
During Q1, Eagle Pharmaceuticals (NASDAQ:EGRX) brought in sales totaling $41.25 million. However, earnings decreased 138.53%, resulting in a loss of $3.77 million. In Q4, Eagle...
Via
Benzinga
Eagle Pharmaceuticals Submits Response to Complete Response Letter from FDA for Vasopressin
June 17, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Return On Capital Employed Overview: Eagle Pharmaceuticals
June 04, 2021
During Q1, Eagle Pharmaceuticals (NASDAQ:EGRX) brought in sales totaling $41.25 million. However, earnings decreased 138.53%, resulting in a loss of $3.77 million. Eagle...
Via
Benzinga
Eagle Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021
May 26, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals to Present at the 2021 RBC Capital Markets Global Healthcare Conference
May 11, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals Inc (EGRX) Q1 2021 Earnings Call Transcript
May 10, 2021
EGRX earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Recap: Eagle Pharmaceuticals Q1 Earnings
May 10, 2021
Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share decreased 71.43% year over...
Via
Benzinga
Eagle Pharmaceuticals Reports First Quarter 2021 Results
May 10, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals Announces Filing of TREAKISYM (bendamustine) Rapid Infusion (“RI”) Liquid Formulation in Japan
May 10, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.